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The selectin family of adhesion molecules and their glycoconjugated ligands are essential for 
blood polymorphonuclear neutrophil (PMN) extravasation into inflammatory and infectious 
sites. However, E-selectin ligands on PMNs are not well characterized. We show here that 
CD44 immunopurified from G-CSF–differentiated 32D cells or from peripheral blood PMNs 
binds specifically to E-selectin. In contrast, CD44 extracted from bone marrow stromal or 
brain endothelial cell lines does not interact with E-selectin, suggesting cell-specific 
posttranslational modifications of CD44. PMN-derived CD44 binding activity is mediated by 
sialylated, 
 
 
 
(1,3) fucosylated, N-linked glycans. CD44 enables slow leukocyte rolling on 
E-selectin expressed on inflamed endothelium in vivo and cooperates with P-selectin 
glycoprotein ligand–1 to recruit neutrophils into thioglycollate-induced peritonitis and 
staphylococcal enterotoxin A–injected skin pouch. CD44 extracted from human PMNs also 
binds to E-selectin. Moreover, we demonstrate that CD44 is hypofucosylated in PMNs from a 
patient with leukocyte adhesion deficiency type II, suggesting that it contributes to the 
syndrome. These findings thus suggest broader roles for CD44 in the innate immune response 
and uncover a potential new target for diseases in which selectins play a prominent role.
 
The selectins are vascular adhesion molecules
interacting with sialylated and fucosylated glycan
determinants, such as sialyl Lewis x, that decorate
the terminal extensions of O- and / or N-linked
carbohydrates (1). They play pivotal roles in
cell–cell interactions among leukocytes, plate-
lets, and endothelial cells (2). Several putative
glycoprotein selectin ligands have been iso-
lated from hematopoietic cells using in vitro
affinity purification techniques (3–6), but the
exact identity and contribution of physiological
E-selectin ligands (ESLs) on PMNs is unknown.
This knowledge gap, despite intense research
effort, originates in part from the unavailability
of inhibitory antibodies, due to the poor immu-
nogenicity of highly glycosylated and conserved
ESL epitopes (7). P-Selectin glycoprotein ligand-1
(PSGL-1) was identified as a ligand for all three
selectins in vivo (8). PSGL-1
 
 
 
/
 
 
 
 mice exhibit
some deficits in E-selectin–mediated rolling but
PSGL-1 appears dispensable for E-selectin–
mediated PMN extravasation, suggesting a role
for other cell surface ESLs (9, 10). An intrigu-
ing report has suggested that CD44 derived
from primitive human hematopoietic stem cells,
but not mature hematopoietic cells, could bind
to E-selectin in vitro (6). The globular amino-
terminal domain of CD44 contains hyaluronic
acid (HA)–binding motifs and several potential
glycosylation sites (see Fig. 1 A). CD44–HA
interaction has been extensively characterized
and shown to mediate a variety of physiologi-
cal and pathological processes, including the
recruitment of activated T cells in extralymphoid
tissues (11), the recovery after noninfectious
lung injury (12), and tumor metastasis (13).
Here, we demonstrate that neutrophil CD44 is
a physiological ESL.
 
RESULTS AND DISCUSSION
 
To assess the ability of mature myeloid cell–
derived CD44 to bind E-selectin, we induced
the differentiation of the 32D cell line with
G-CSF (Fig. 1, B and C). After 4 d of G-CSF
treatment, the majority (68 
 
 
 
 1%) of 32D cells
exhibited a polymorphonuclear appearance.
Differentiated 32D cells bound to soluble
E-selectin, and binding was abrogated by che-
lation of divalent cations or by prior treatment
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of the cells with sialidase. Protein extracts from the same cells
were incubated with immunomagnetic beads coated with
anti-CD44. Immobilized CD44 bound to soluble E-selectin
in a manner similar to intact cells; binding was eliminated
with EDTA or by sialidase treatment before lysis (Fig. 1 C).
No binding was observed when beads were coated with an
isotype-matched antibody binding 
 
 
 
M
 
 
 
2 integrin, or with
control rat IgG (unpublished data). Immunoblot analyses re-
vealed that CD44 was the sole protein purified from anti-
CD44–coated beads (Fig. S1, available at http://www.jem.
org/cgi/content/full/jem.20042014/DC1). These results
thus suggest that CD44 derived from mature myeloid cells
interacts specifically with E-selectin. Further, we evaluated
E-selectin binding specificity using CD44 extracted from a
bone marrow stromal cell line (MS-5) and a brain endothe-
lial cell line (bEnd.3), which express high levels of CD44 but
do not bind to E-selectin. CD44 immunopurified from en-
dothelial and stromal cells did not interact with E-selectin
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20042014/DC1), underscoring differential posttransla-
tional modifications of CD44 between hematopoietic and
nonhematopoietic cells.
To investigate the contribution of O-linked and
N-linked carbohydrates in the formation of ESLs on myeloid
cells, we treated G-CSF–differentiated 32D cells with 
 
O
 
-sia-
loglycoprotein endopeptidase (OSGE) to remove 
 
O
 
-glycans.
OSGE affected neither ESLs on the cell surface, nor E-selec-
tin binding to immunopurified CD44 (Fig. 1 D), whereas
P-selectin ligands were completely cleaved by OSGE (un-
published data). To assess the contribution of N-linked car-
bohydrates, ESLs were removed with sialidase and differenti-
ated 32D cells were then cultured in the presence or absence
of tunicamycin. De novo synthesis of ESL determinants on
CD44 was dramatically inhibited (
 
 
 
90%, P 
 
 
 
 0.002) by in-
cubation with tunicamycin and the addition of OSGE to tu-
nicamycin-treated cells did not further reduce E-selectin
binding (Fig. 1 D). Tunicamycin treatment, however, did
not affect P-selectin binding (which is dependent on 
 
O
 
-gly-
cosylation; Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20042014/DC1). Thus, CD44 derived
Figure 1. Neutrophil CD44 binds to E-selectin through N-linked 
glycans. (A) Structure of CD44 molecule. The globular amino-terminal 
domain of CD44 proteins contains several potential O- (circle) or N- 
(diamond) glycosylation sites (for review see reference 31). (B) Binding 
of E-selectin–IgM chimera to 32D cells differentiated for 4 d in media 
containing 10 ng/ml G-CSF. All 32D cells bind to E-selectin (left, open 
histogram) and binding is abrogated by treatment with EDTA (5 mM; 
gray-filled histograms) or sialidase treatment (right, open histogram). 
(C) Binding of E-selectin to CD44 immunopurified from the same 32D 
cells. (D) Contributions of O- and N-glycans in CD44 binding to E-selectin. 
Differentiated 32D cells were either treated with OSGE, sialidase, or 
vehicle before immunopurification of CD44. In the last three bars, ESLs 
were removed by sialidase and cells were allowed to recover for 36 h 
in the presence or absence of tunicamycin (15  g/ml) to inhibit
N-glycosylation. Data are average geometric mean values from at least 
three independent experiments. **, P   0.003. (E) PMN-derived CD44 is 
an ESL. PMNs were isolated from (i, iv, and vii) BM and (ii, v, and viii) 
blood of control mice, or (iii, vi, and ix) blood from FucT IV/VII /  mice. 
Upper panels (i–iii) show CD44 expression on PMNs (gated on Gr-1hi). 
Middle panels (iv–vi) depict E-selectin binding on PMNs (Gr-1hi). Lower 
panels (vii–ix) show binding of E-selectin on immobilized CD44 extracted 
from purified PMNs (purity  95%). Gray-filled histograms represent 
isotype-matched control (CD44 staining) or EDTA treatment (E-selectin 
binding). (F and G) ESLs on wild-type and CD44 /  PMNs. Blood leuko-
cytes were stained with E-selectin–IgM to determine ESL densities. 
(F) Histograms of E-selectin binding on Gr-1hi PMNs. (G) Geometric mean 
fluorescence of E-selectin binding on blood Gr-1hi PMNs. n   12 mice 
per group. *, P   0.02. 
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from mature myeloid cell binds to E-selectin through
N-linked, but not O-linked, glycans.
We next assessed E-selectin binding on primary mouse
PMNs. BM and peripheral blood (PB) PMNs (Gr-1
 
hi
 
) ex-
press high levels of CD44 but expression of ESLs is hetero-
geneous on BM PMNs whereas PB PMNs uniformly ex-
press high levels of ESLs (Fig. 1 E). E-Selectin binding to
CD44 displayed a pattern similar to that of intact cells in
that binding was lower on CD44 extracted from BM PMNs
than on PB PMNs (Fig. 1 E), suggesting that the density of
CD44 molecules that are appropriately decorated with
E-selectin binding carbohydrates is greater on circulating
PMNs than on maturing bone marrow PMNs. No binding
was observed when beads were coated with anti-
 
 
 
M inte-
grin or rat IgG (Fig. S2), or when CD44 was extracted from
blood PMNs deficient in 
 
 
 
(1,3) fucosyltransferase IV and
VII (FucT IV/VII
 
 
 
/
 
 
 
; Fig. 1 E; reference 14). These results
further validate the binding specificity of the assay and indi-
cate that CD44 is a physiological target of leukocyte FucTs.
Fluid-phase binding of E-selectin to peripheral blood
PMNs, an assay largely PSGL-1–dependent (10), was signif-
icantly reduced in CD44
 
 
 
/
 
 
 
 PMNs compared with wild-
type control PMNs (Fig. 1, F and G). Taken together, these
data clearly indicate that CD44 from PB neutrophils binds
to E-selectin.
E-selectin closely cooperates with P-selectin in promot-
ing PMN–endothelial interactions and PMN extravasation;
mice lacking both endothelial selectins have much more se-
vere defects than either singly deficient animals (15–18).
E-Selectin–deficient mice display increased leukocyte rolling
velocities, suggesting that it is critical in forming stronger ad-
hesion bonds between endothelial cells and PMNs (19).
However, leukocyte rolling velocities were not altered in
PSGL-1
 
 
 
/
 
 
 
 mice (10), suggesting that another leukocyte
ESL mediates the slow rolling. We intercrossed CD44
 
 
 
/
 
 
 
with PSGL-1
 
 
 
/
 
 
 
 mice to characterize the function of CD44
in E-selectin–mediated leukocyte-endothelial interactions.
Double knockout (DKO) animals were viable, fertile, and
displayed a significant increase in circulating leukocytes,
including PMNs, monocytes and eosinophils (Table S1,
available at http://www.jem.org/cgi/content/full/jem.
20042014/DC1). We subjected age-matched male wild-
type, CD44
 
 
 
/
 
 
 
, PSGL-1
 
 
 
/
 
 
 
, and DKO mice to intravital
microscopic examination of TNF-
 
 
 
–treated cremaster mus-
cle to explore the ability of CD44 to interact with E-selectin
in vivo. Consistent with previous studies (9, 10) and with
the notion that P-selectin mediates most rolling activity in
inflamed venules, the rolling fraction was significantly re-
duced in PSGL-1
 
 
 
/
 
 
 
 mice (Fig. 2 A and Table S2). Residual
rolling activity in PSGL-1
 
 
 
/
 
 
 
 mice was further reduced by
Figure 2. Intravital microscopy of TNF- –stimulated cremaster 
muscle venules. Leukocyte behavior in cremasteric venules was recorded 
between 150 and 210 min after TNF-  administration for off-line analyses. 
(A) Rolling flux fraction in wild-type (WT, n   63 venules), WT treated 
with hyaluronidase (WT   Hase, n   51), CD44 /  (n   79), PSGL-1 /  
(n   50), and DKO (n  59) mice. (B–D) The velocity of 2,610 rolling leu-
kocytes from the five groups of mice was measured over 2 s (also see 
Fig. S4). (B) Mean rolling velocities. (C) Cumulative histograms of rolling 
velocities. (D) Cumulative histograms of transit times calculated per 
100  m of venule segment. Five-group comparisons were analyzed by 
one-way ANOVA with Bonferroni/Dunn post hoc test. **, P   0.001 
(1% risk level) compared with WT group or between indicated two groups. 
E-SELECTIN IN VIVO | Katayama et al.
 
1186
 
 
 
30% in mice lacking both PSGL-1 and CD44, although
this did not reach the threshold statistical significance in a
multigroup analysis of variance (Fig. 2 A). Although the av-
erage velocity of rolling leukocytes was similar between
PSGL-1
 
 
 
/
 
 
 
 and wild-type mice (Fig. 2, B and C and Fig.
S4, available at http://www.jem.org/cgi/content/full/jem.
20042014/DC1), leukocyte rolling velocities were signifi-
cantly increased in CD44
 
 
 
/
 
 
 
 mice (P 
 
 
 
 0.0001). More-
over, rolling velocities were further increased when both
CD44  and PSGL-1 were absent (Fig. 2 B, P 
 
 
 
 0.0002,
comparison CD44
 
 
 
/
 
 
 
 with DKO group). In keeping with
the velocity analyses, the median transit times of rolling leu-
kocytes were much shorter in CD44
 
 
 
/
 
 
 
 than wild-type or
PSGL-1
 
 
 
/
 
 
 
 mice, and even more rapid in DKO mice (Fig. 2
D). Because CD44 is known to interact with HA, we treated
wild-type mice with hyaluronidase at a dose previously
shown to alter CD44-mediated lymphocytes recruitment
(11). Hyaluronidase treatment neither influenced the leuko-
cyte rolling flux nor affected leukocyte rolling velocities and
transit times (Fig. 2 and Fig. S4). Thus, these data indicate
that CD44 binding to E-selectin and not HA primarily con-
trols the velocity of rolling, and that PSGL-1 can also con-
tribute to this activity when CD44 is absent.
To investigate whether CD44 binding to E-selectin can
mediate the extravasation of PMNs into inflammatory sites,
we injected mice with thioglycollate, a chemical that induces
a severe peritoneal inflammation. In this model, PMN re-
cruitment is initially (0–4 h) P-selectin dependent but subse-
quently (8 h) requires E-selectin expression (15, 17). Previ-
ous studies have revealed no significant defect in PMN
recruitment 8 h after thioglycollate injection in PSGL-1
 
 
 
/
 
 
 
mice (9). Wild-type, CD44
 
 
 
/
 
 
 
, PSGL-1
 
 
 
/
 
 
 
, and DKO mice
were thus treated with thioglycollate, and the number of
PMNs in the peritoneal exudate was evaluated 8 h after in-
jection. Although there was no significant reduction in
PMN counts in CD44
 
 
 
/
 
 
 
 and PSGL-1
 
 
 
/
 
 
 
 mice, the recruit-
ment of PMNs was significantly reduced (by 44%, P 
 
 
 
0.005) in DKO mice (Fig. 3 A). Because thioglycollate may
not reproduce physiological inflammation, we also evaluated
PMN extravasation elicited by the staphylococcal entero-
toxin A (SEA) in a preformed air pouch model (20). In
preliminary experiments using P- and E-selectin–deficient
mice, we ascertained that SEA-mediated PMN recruitment
was selectin dependent (unpublished data). We then instilled
SEA in dorsal skin pouches of mice from the four genotypes
to assess the contribution of CD44 and PSGL-1 in this
model. We found a severe reduction in the extravasation of
PMNs 6 h after SEA injection in DKO mice compared with
wild-type controls (77% reduction, P 
 
 
 
 0.006), whereas the
numbers of extravasated PMNs were not significantly altered
in either singly-deficient mice (Fig. 3 B). To exclude further
the possibility that the reduced recruitment of PMNs ob-
served in DKO mice was due to CD44 binding to HA, we
repeated the thioglycollate-induced extravasation experi-
ments in PSGL-1
 
 
 
/
 
 
 
 mice treated with hyaluronidase (20 U
i.v.) or vehicle. Hyaluronidase treatment did not significantly
alter PMN recruitment (Fig. 3 C). Although we cannot
completely rule out the possibility that extravascular HA
may have remained available for PMN migration, the results
from these two models strongly suggest that CD44 is an ESL
that cooperates with PSGL-1 in PMN extravasation into in-
flamed sites.
Because CD44 is expressed on both leukocyte and endo-
thelial cells, we wished to clarify further whether CD44 de-
ficiency on PMNs was sufficient to account for impaired
PMN extravasation. We generated chimeric mice by trans-
plantation of a mixture of PSGL-1
 
 
 
/
 
 
 
CD44
 
 
 
/
 
 
 
 and PSGL-
1
 
 
 
/
 
 
 
CD44
 
 
 
/
 
 
 
 BM-nucleated cells into lethally irradiated
Figure 3. Neutrophil extravasation into inflammatory sites. 
(A) Thioglycollate-induced peritonitis. Extravasated PMNs were determined 
8h after the i.p. injection of thioglycollate (n   7). (B) SEA-induced 
inflammation model. Extravasated PMNs were quantified 6 h after 
instillation of SEA into preformed skin pouches (n   6). Data are repre-
sented by box-and-whisker plots wherein each box represents an inter-
quartile range (central 50%), the median is shown by the horizontal 
lines, and vertical lines show the full range of data points. Four-group 
comparisons were analyzed by one-way ANOVA with Bonferroni/Dunn 
post hoc test. *, P   0.0083 (5% risk level) compared with WT group. 
(C) Hyaluronidase treatment does not affect PMN recruitment. PSGL-1 /  
mice were injected i.v. with 20 U of hyaluronidase or PBS before i.p. 
injection of thioglycollate. Each circle represents the value of an individual 
PSGL-1 /  mouse. P   0.24. 
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wild-type recipients. 6 wk after transplantation, 
 
 
 
96% Gr-1
 
hi
 
leukocytes did not express PSGL-1. Peritoneal inflammation
was then induced by thioglycollate for 8 h, and the ratios of
PSGL-1
 
 
 
/
 
 
 
CD44
 
 
 
/
 
 
 
 PMNs over DKO PMNs in blood and
peritoneal exudates were assessed by FACS (Fig. 4 A). In this
competitive setting, we found that PSGL-1
 
 
 
/
 
 
 
CD44
 
 
 
/
 
 
 
PMNs were preferentially recruited in the peritoneum (an
approximate twofold increase) over those that did not ex-
press PSGL-1 and CD44 (Fig. 4 B), suggesting that neutro-
phil rather than endothelial CD44 plays a critical role for mi-
gration into inflammatory sites.
Our data suggest that ESLs may have specialized func-
tions. It is interesting to speculate that this may be controlled
by the spatial distribution on the cell surface. For example,
PSGL-1 is primarily a tethering molecule localized on the tip
of microvilli (21), whereas we show here that CD44, a recep-
tor located on the cell body (22, 23), primarily controls roll-
ing velocity. It is notable that 
 
 
 
2 integrins, which can also
mediate slow rolling (24), are located on the cell body. Thus,
our data are consistent with the notion that adhesion recep-
tors located on microvilli may determine tethering efficiency
but not rolling velocity (23, 25). As suggested by the partial
defect in leukocyte rolling and recruitment of DKO mice,
other functional ESLs exist on PMNs. The various ESLs may
exert distinct functions in E-selectin–dependent adhesive and
migratory activities. Further studies are needed to ascertain in
vivo functions of major candidate ESL glycoproteins, includ-
ing ESL-1 (expressed on mouse microvilli of myeloid cells; 7)
and L-selectin (candidate ESL on human PMNs; 22, 26).
To investigate whether human neutrophil CD44 was a
functional ESL, we purified peripheral blood PMNs from
healthy donors and extracted PMN-derived human CD44
from cell lysates for the E-selectin binding assay. To control
for binding specificity, we used sialidase-treated PMNs from
the same donors and PMNs from a patient with leukocyte
adhesion deficiency type II (LADII), characterized by a com-
plete deficit in functional selectin ligands due to G588 nucle-
otide deletion in the GDP–fucose transporter gene (27). As
shown in Fig. 5 A, healthy PMN-derived CD44 immobi-
lized on beads bound to soluble E-selectin, and binding was
abrogated when cells were treated with sialidase before the
preparation of the lysates. In contrast, CD44 extracted from
LADII PMNs did not appreciably bind to E-selectin (Fig. 5
B), despite normal expression of CD44 (Fig. 5, insets). Inter-
estingly, a short incubation of LADII PMNs with recombi-
nant FucTVI enabled CD44 to bind normally to E-selectin,
indicating that CD44 on these cells possesses terminal N-gly-
cans that can be modified by extracellular FucT activity (Fig.
5 C). The rescue of selectin ligand activity by treatment with
FucTVI may represent an effective therapy to prevent infec-
tious episodes associated with this syndrome.
Figure 4. Competitive recruitment of neutrophils into inflammatory 
sites. Wild-type recipient mice were lethally irradiated and transplanted 
with mixture of BM cells from PSGL-1 / CD44 /  and PSGL-1 / CD44 /  
mice. 6 wk after transplantation, PMNs were elicited by thioglycollate 
for 8 h. Blood and peritoneal exudates were analyzed by FACS. (A) Repre-
sentative dot plots for CD44 and PSGL-1 in Gr-1hi cells from blood and 
peritoneum. (B) Ratios PSGL-1 / CD44 /  over PSGL-1 / CD44 /  Gr-1hi 
cells. Bars show mean values. n   4, *, P   0.01.
Figure 5. Human neutrophil CD44 binds to E-selectin. PMNs were 
purified from healthy donors or from a patient with LADII. PMNs were 
treated with sialidase or incubated with vehicle. (A) CD44 derived from 
healthy PMNs binds to E-selectin (empty red histogram), and binding is 
abrogated by sialidase (green-filled histogram). (B) In contrast, there is no 
difference in E-selectin binding to immunopurified CD44 between sialidase-
treated and sham-treated LADII PMNs. (C) Incubation of LADII PMNs with 
recombinant FucTVI (20 mU/ml, 40 min at 37 C) and GDP-fucose (1 mM) 
restores the ability of human CD44 to bind to E-selectin.E-SELECTIN IN VIVO | Katayama et al. 1188
In summary, these data clearly indicate that CD44 is a
physiological ESL on mature human and mouse myeloid cells.
CD44 is widely expressed in multiple cell types but only he-
matopoietic cells bind to E-selectin, indicating that the affinity
for E-selectin is regulated by cell-specific posttranslational
modifications. Selective binding to E-selectin (myeloid cells)
or HA (activated T cells) endows CD44 with pivotal func-
tions at the nexus of innate and adaptative immunity.
MATERIALS AND METHODS
Cell lines and E-selectin/IgM chimeric protein. The 32D mouse
myeloid progenitor cell line (American Type Culture Collection) was cul-
tured in RPMI containing 10% FBS (Hyclone) and 10% Wehi-3B (a murine
IL-3–secreting cell line) conditioned medium. Differentiation of 32D cells
was induced with 10 ng/ml recombinant human G-CSF (R&D Systems) for
4 d. Mouse BM-derived stromal cell line MS-5 was cultured in  MEM con-
taining 10% FBS, and mouse endothelial cell line bEnd.3 (American Type
Culture Collection) was cultured in DMEM containing 10% FBS.
Murine E-selectin/IgM chimera was produced by the transfection of
293T cells with E-selectin/IgM DNA vector using Lipofectamine 2000 (In-
vitrogen). Saturating concentrations of culture supernatants were used for
the fluid-phase selectin binding assay.
Glycan analyses. 32D cells or purified PMNs were treated with 150 mU
sialidase from Arthrobacter ureafaciens (Roche), or with 20  g OSGE (par-
tially purified by membrane diafiltration and isoelectric point precipitation
from Pasteurella haemolytica; Cedarlane) for 1 h at 37 C in HBSS media con-
taining 20 mM Hepes and 0.1% human serum albumin (Baxter). Both treat-
ments completely eliminated P-selectin ligands. Inhibition of N-glycosyla-
tion was achieved by culture of sialidase-treated 32D cells in the presence or
absence of 15  g/ml tunicamycin (Calbiochem) for 36 h.
Preparation of murine and human neutrophils. Age-matched (6–12
wk) C57BL/6 (NCI, Frederick Cancer Research and Developmental Cen-
ter) and FucT IV/VII /  mice (14; provided by John B. Lowe, University
of Michigan Medical School, Ann Arbor, MI) were used as BM and blood
donors. In some experiments, lymphopenic NOD/SCID mice were used as
blood donor to obtain greater PMN purity. Expression of ESLs and binding
of E-selectin to CD44 were similar between C57BL/6- and NOD/SCID-
derived PMNs. BM cells were harvested by flushing femora in RPMI using
21-gauge needle and blood was harvested by retroorbital sampling using
heparinized capillary tubes. For blood PMNs purification, RBCs were de-
pleted by blood sedimentation in 0.1% methylcellulose for 30 min at room
temperature. Cells remaining in the supernatant were washed and resus-
pended in PBS containing 0.5% BSA and 2 mM EDTA, and PMNs sepa-
rated by overlaying on a Percoll gradient (65% in HBSS). Contaminating
RBCs were lysed with 0.8%NH4Cl.
Human neutrophils were purified from human venous blood as de-
scribed previously (27). Human blood samples were obtained in accordance
with protocols approved by the Internal Review Board of Mount Sinai.
Flow cytometry and E-selectin binding assay. Cells were stained by
incubation with 10  g/ml of a biotin-labeled anti-CD44 antibody (clone
IM7; BD Biosciences) or control antibody followed by incubation with CY5-
conjugated streptavidin (Jackson ImmunoResearch Laboratories), and washed
in PBS before analysis by flow cytometry. For the fluid-phase selectin binding
assay, cells or CD44-coated beads were incubated with E-selectin/IgM chi-
mera followed by incubation with Cy5-conjugated anti–human IgM anti-
body (1:50 dilution; Jackson ImmunoResearch Laboratories) as described pre-
viously (28). Control samples were stained in the presence of 5 mM EDTA.
A similar procedure was followed for staining with the P-selectin/IgM chi-
mera. For staining of murine PMNs, 50  l of blood or 105 BM mononuclear
cells were incubated with FITC-conjugated anti–Gr-1 antibody (BD Bio-
sciences) and then labeled with the E-selectin chimera as described above.
PMNs were gated on the basis of high Gr-1 expression. All incubations were
performed at 6 C for 15 min. Samples were analyzed using a FACSCalibur
flow cytometer and the CellQuest software (Becton Dickinson).
Preparation of immunomagnetic beads for E-selectin binding
analyses. Lysates were prepared by incubation of cells in lysis buffer (50
mM Tris-HCl, pH 7.5, 1% Triton X-100, 150 mM NaCl, and 1 mM CaCl2
plus 0.1 M PMSF and protease inhibitor cocktail; Sigma-Aldrich) for 30 min
on ice and cell debris were removed by centrifugation at 14,000 rpm for 10
min at 4 C. Anti–rat IgG-coated beads (106 M-450 Dynabeads; Dynal) were
incubated with 2.5  g anti-CD44 (IM7), anti- M integrin (M1/70 from
American Type Culture Collection, purified from hybridoma supernatants)
or rat IgG (Sigma-Aldrich) for 4 h at 4 C under rotation. Beads were then
washed twice in cold lysis buffer and incubated overnight with the appropri-
ate cell lysates (2   106 cells/106 beads) at 4 C under rotation. Beads were
washed once in cold lysis buffer and once in cold RPMI containing 5% FBS
and 0.05% NaN3 before fluid-phase E-selectin binding assay.
In vivo models of leukocyte recruitment. Leukocyte-endothelial in-
teractions were assessed using intravital microscopy of the cremaster muscle
as described previously (29). More detailed information is available at http:
//www.jem.org/cgi/content/full/jem.20042014/DC1. PMN recruitment
in the thioglycollate-induced peritonitis model was assessed as described
(15, 17). In some experiments, mice were injected i.v. with 20 U of hyal-
uronidase (Sigma-Aldrich) or control PBS before injection of thioglycollate.
SEA-induced inflammation in air pouch was performed as described else-
where (20). In brief, air pouches were raised on the dorsum by s.c. injec-
tions of 2.5 ml sterile air on days 0 and 3 and the pouch was allowed to
form until day 6. On day 6, 10  g of SEA (endotoxin  1 EU/mg; Toxin
Technology) in 1 ml PBS was injected in the pouch. Mice were killed 6 h
after SEA instillation, and the pouches were washed with 5 ml of PBS con-
taining 1% BSA, 0.5 mM EDTA, and 10 U/ml heparin. Total cell numbers
in the peritoneal and air pouch exudates were determined by hemocytome-
ter. Differential leukocyte counts were determined from Wright-stained
cytospin preparations. All animal experimental procedures were approved
by the Animal Care and Use Committee of Mount Sinai.
Generation of PSGL-1/CD44 double-deficient mice. PSGL-1 / 
mice were generated by gene targeting (9) and provided by Bruce Furie
(Harvard Medical School, Boston, MA). CD44 /  mice were also gener-
ated by gene targeting (30) and purchased from The Jackson Laboratory.
PSGL-1 /  mice were intercrossed with CD44 /  mice to generate dou-
ble-heterozygous animals. These doubly heterozygous mice were then bred
to yield wild-type control, CD44 / , PSGL-1 / , and double-deficient
mice. The genotypes were determined by PCR using primers and condi-
tions detailed in supplemental materials. Separate colonies of each genotype
were then expanded to yield age- and sex-matched experimental mice with
similar mixed background.
Generation of chimeric mice and competitive recruitment assay.
Wild-type–recipient mice were lethally irradiated (12 Gy, split dose) and
transplanted with 1.5   106 PSGL-1 /  BM-nucleated cells and 1.5   106
PSGL-1/CD44 double deficient (DKO) BM-nucleated cells. 6 wk after
transplantation, engraftment was confirmed by FACS. Leukocytes from
thioglycollate-induced exudates were stained with FITC-conjugated anti–
Gr-1 antibody (BD Biosciences), PE-conjugated anti-CD44 antibody
(KM201; Southern Biotechnologies Associates), and biotin–anti–PSGL-1
antibody (clone 4RA10; gift of Dr. Dietmar Vestweber, The Institute of
Cell Biology, University of Münster, Münster, Germany), followed by
Cy5-conjugated streptavidin (Jackson ImmunoResearch Laboratories).
Online supplemental material. Online supplemental materials contain
detailed information about genotyping of mutant mice, intravital micros-
copy studies, and statistical analyses. Figs. S1 and S2 further evaluate theJEM VOL. 201, April 18, 2005 1189
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specificity of E-selectin binding to CD44-coated beads. Fig. S3 shows the
effect of tunicamycin treatment on O-glycosylation. Fig. S4 shows the leu-
kocyte rolling velocity distributions in TNF- –treated cremaster muscle
venules. Table S1 shows peripheral blood counts and Table S2 details venu-
lar hemodynamic parameters of intravital microscopy experiments. Online
supplemental material is available at http://www.jem.org/cgi/content/full/
jem.20042014/DC1.
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